The 6-min walk test as a primary end-point in interstitial lung disease

There is a need for clinical trial end-points to better assess how patients feel and function, so that interventions can be developed which alleviate symptoms and improve quality of life. Use of 6-min walk test (6MWT) outcomes as a primary end-point in interstitial lung disease (ILD) trials is growi...

Descripción completa

Detalles Bibliográficos
Autores principales: Harari, Sergio, Wells, Athol U., Wuyts, Wim A., Nathan, Steven D., Kirchgaessler, Klaus-Uwe, Bengus, Monica, Behr, Jürgen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724818/
https://www.ncbi.nlm.nih.gov/pubmed/36002171
http://dx.doi.org/10.1183/16000617.0087-2022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724818/
https://www.ncbi.nlm.nih.gov/pubmed/36002171
http://dx.doi.org/10.1183/16000617.0087-2022

Ejemplares similares